Hodgkin's Lymphoma Clinical Trial
Official title:
Prognosis of Patients With Relapsed/Refractory Hl Treated With Combination of Ifosfamide, Gemcitabine and Vinorelbine(IGEV) Induction Therapy Before High-dose Chemotherapy (HDCT) With Autologous Hematopoietic Stem Cells Transplantation (AHSCT)
This is a retrospective analysis of a homogeneous cohort of patients with
relapsed/refractory HL that received IGEV scheme as induction therapy to HDCT and AHSCT for
reassess the most common prognostic factors and try to identify a prognostic score with
clinical and therapeutic relevance by using 6 clinical tools:
1. B symptoms(yes/no)
2. relapse in previously irradiated areas(yes/no)
3. Ann Arbor Stage (III/IV vs I/II)
4. disease status at accrual (refractory vs relapsed)
5. Early relapse within 12 months of Complete Response (CR) versus late relapse after
Complete Response (CR) lasting > l2 months",
6. extranodal involvement (yes/no).
n/a
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03776864 -
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
|
Phase 2 | |
| Recruiting |
NCT02356159 -
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
|
Phase 1/Phase 2 | |
| Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
| Terminated |
NCT01699581 -
Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant
|
Phase 2 | |
| Completed |
NCT00784537 -
High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
| Recruiting |
NCT05355051 -
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
|
Phase 2 | |
| Completed |
NCT00520130 -
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01316146 -
Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
|
Phase 1 | |
| Completed |
NCT02223052 -
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT02581007 -
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
|
Phase 2 | |
| Terminated |
NCT01745913 -
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
|
Phase 2 | |
| Recruiting |
NCT04665063 -
A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma
|
N/A | |
| Recruiting |
NCT02259556 -
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
|
Phase 1/Phase 2 | |
| Completed |
NCT02003625 -
Meloxicam vs Placebo for Mobilization
|
Phase 2 | |
| Terminated |
NCT01742793 -
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
|
Phase 1 | |
| Completed |
NCT01402687 -
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)
|
N/A | |
| Terminated |
NCT00901303 -
Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma
|
N/A | |
| Completed |
NCT00283439 -
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01272817 -
Nonmyeloablative Allogeneic Transplant
|
N/A |